Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome, a biopharmaceutical company focused on first-in-class antibody therapeutics, announced that its President and CEO, Purnanand Sarma, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, at 10:30 a.m. ET. The presentation can be accessed via a live audio webcast on the company’s website, with a replay available for 30 days. Immunome leverages its human memory B cell discovery engine to develop therapies for oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) has appointed Andrew D. Badley, M.D., to its COVID-19 Advisory Board. Dr. Badley, Chair of the Mayo COVID-19 Research Taskforce, is recognized for his expertise in infectious diseases and will provide critical insights as Immunome develops antibody therapeutics for COVID-19 and other outbreaks. His extensive background includes significant roles at the Mayo Clinic and a focus on virus-host interactions, aiming to enhance therapeutic approaches in infectious diseases.
Immunome (Nasdaq: IMNM) has appointed Dr. Franklyn G. Prendergast to its Board of Directors, enhancing its leadership during a pivotal transition from preclinical to clinical stages. Dr. Prendergast, recognized for his extensive medical and academic experience, aims to contribute to the development of antibody therapeutics targeting diseases with unmet needs. Concurrently, Michael Widlitz, a long-serving director, will transition to an advisory role in Medical Affairs. This strategic management change is expected to leverage Immunome's innovative platform for therapeutic advancement.
Immunome, Inc. (Nasdaq: IMNM) has announced that Purnanand Sarma, Ph.D., President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 8:00 a.m. ET. Interested parties can access the live audio webcast through the Investor Relations section of the company's website, with a replay available for 30 days after the event. Immunome focuses on developing first-in-class antibody therapeutics using its human memory B cell discovery engine, targeting oncology and infectious diseases, including COVID-19.
Immunome, Inc. (Nasdaq: IMNM) announced a $4.3 million funding increase from the U.S. Department of Defense, raising total support to $17.6 million for its antibody cocktail, IMM-BCP-01, aimed at combating SARS-CoV-2. This additional capital will facilitate the expansion of clinical studies following FDA feedback. The antibody cocktail, comprising three monoclonal antibodies, targets multiple SARS-CoV-2 variants with high affinity. Immunome is working towards an IND filing for IMM-BCP-01 in late 2Q/early 3Q 2021.
Immunome, a biopharmaceutical company focused on antibody therapeutics, reported its Q1 2021 financial results, revealing a net loss of $3.9 million and R&D expenses of $2.0 million. The company announced significant advancements, including the discovery of antibodies neutralizing SARS-CoV-2 variants and plans for an IND filing for the IMM-BCP-001 cocktail in late Q2 or early Q3 2021. Additionally, Immunome appointed Dr. Dennis Giesing as Chief Development Officer and Corleen Roche as Chief Financial Officer. A $27 million private placement is expected to fund operations through 2022.
Immunome, Inc. (Nasdaq: IMNM) announced antibody selection for its IMM-BCP-01 cocktail, showing effectiveness against SARS-CoV-2 variants in preclinical tests. The cocktail, comprising three monoclonal antibodies, demonstrated full neutralization against several variants, including those resistant to current therapeutics. The company plans to file an IND for IMM-BCP-01 in late Q2/early Q3 2021, supported by a $13.3 million agreement with the U.S. Department of Defense. Immunome aims to pioneer treatments for oncology and infectious diseases through its patient memory B cell platform.
Immunome (Nasdaq: IMNM) has entered into a definitive securities purchase agreement to sell its equity securities in a private placement, securing approximately $27 million in gross proceeds. The deal involves the sale of 1,000,000 units at $27.00 per unit, each comprising one share of common stock and a warrant for an additional half share at $45.00 per share. Funds will support the development of its oncology and infectious disease portfolio, including COVID-19. The transaction is expected to close on April 28, 2021, pending customary conditions.
Immunome, Inc. (Nasdaq: IMNM) has appointed Corleen Roche as the new Chief Financial Officer. Roche, with extensive experience in corporate finance in the biopharmaceutical sector, previously served as U.S. CFO for Biogen. Her appointment is expected to enhance Immunome's growth into a clinical-stage company, strengthening its financial strategy and business development efforts. Roche aims to leverage her expertise to advance Immunome's therapeutic pipeline, which focuses on oncology and infectious diseases, including COVID-19.
Immunome (Nasdaq: IMNM) announced the appointment of Dennis Giesing, Ph.D., as Chief Development Officer, effective immediately. Dr. Giesing brings over 35 years of pharmaceutical experience, having previously worked at Johnson & Johnson Oncology and Taris Biomedical. His role will include leading product development and clinical strategies, with two IND filings planned for 2021. CEO Purnanand Sarma expressed confidence in Dr. Giesing's ability to advance Immunome's antibody therapeutics aimed at oncology and infectious diseases, including COVID-19.